Core Viewpoint - Actinium Pharmaceuticals (ATNM) has shown strong year-to-date performance, significantly outperforming the average returns of the Medical sector [1][4]. Company Performance - Actinium Pharmaceuticals has returned approximately 34.1% since the beginning of the calendar year, while the average return for stocks in the Medical sector is about 7% [4]. - The Zacks Consensus Estimate for ATNM's full-year earnings has increased by 11.7% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [4]. Industry Context - Actinium Pharmaceuticals is part of the Medical - Drugs industry, which consists of 146 individual companies and currently ranks 70 in the Zacks Industry Rank [6]. - Stocks within the Medical - Drugs industry have gained about 7.1% year-to-date, showing that ATNM is performing better than its peers in this specific industry [6]. Comparison with Peers - Collegium Pharmaceutical (COLL), another stock in the Medical sector, has outperformed the sector with a year-to-date return of 70.6% and has a Zacks Rank of 1 (Strong Buy) [5]. - The consensus EPS estimate for Collegium Pharmaceutical has increased by 9.1% over the past three months, reflecting a positive outlook similar to that of Actinium Pharmaceuticals [5].

Core Insights - Three stocks with strong value characteristics and a buy rank are highlighted for investors: Kimball Electronics, Collegium Pharmaceutical, and James River Group Holdings [1][2][3] Group 1: Kimball Electronics, Inc. (KE) - Kimball Electronics provides electronics manufacturing and contract manufacturing services for automotive, medical, and industrial markets [1] - The company has a Zacks Rank of 1 and a price-to-earnings ratio (P/E) of 21.53, compared to 24.96 for the S&P 500 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 8.8% over the last 60 days [1] Group 2: Collegium Pharmaceutical, Inc. (COLL) - Collegium Pharmaceutical is a specialty pharmaceutical company [2] - It also carries a Zacks Rank of 1 and has a P/E ratio of 6.45, significantly lower than the S&P 500's 24.96 [2] - The Zacks Consensus Estimate for its current year earnings has risen by 6.6% over the last 60 days [2] Group 3: James River Group Holdings, Ltd. (JRVR) - James River Group is a specialty insurance company [3] - The company holds a Zacks Rank of 1 and has a P/E ratio of 6.30, compared to 8.90 for the industry [3] - The Zacks Consensus Estimate for its current year earnings has increased by 10.5% over the last 60 days [3]

Group 1 - Guardant Health (GH) has significantly outperformed the Medical sector in 2023, with a year-to-date return of approximately 246.8% compared to the sector's average return of 7% [4] - The Zacks Rank for Guardant Health is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for GH's full-year earnings has increased by 3.7% over the past quarter, reflecting improving analyst sentiment [3] Group 2 - Guardant Health is part of the Medical - Biomedical and Genetics industry, which consists of 467 stocks and is currently ranked 77 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Biomedical and Genetics industry this year is 20%, indicating that Guardant Health is performing better than its peers [5] - Another notable stock in the Medical sector, Collegium Pharmaceutical (COLL), has a year-to-date return of 67% and is ranked 1 (Strong Buy) in the Zacks Rank [4][5]

Core Viewpoint - Collegium Pharmaceutical (COLL) has demonstrated strong stock performance, with a 33.5% increase over the past month and a 67% gain since the beginning of the year, significantly outperforming the Zacks Medical sector and the Zacks Medical - Drugs industry [1][2]. Financial Performance - The company has consistently exceeded earnings expectations, reporting an EPS of $2.25 against a consensus estimate of $1.88 in its last earnings report [2]. - For the current fiscal year, Collegium is projected to achieve earnings of $7.55 per share on revenues of $783.93 million, reflecting a 17.05% increase in EPS and a 24.15% increase in revenues [3]. - The following fiscal year is expected to see a slight decline in EPS to $7.4 per share, with revenues increasing to $807.27 million, indicating a year-over-year change of -2.03% in EPS and 2.98% in revenues [3]. Valuation Metrics - Collegium Pharmaceutical's stock trades at a valuation of 6.3X current fiscal year EPS estimates, significantly lower than the peer industry average of 19.3X [7]. - On a trailing cash flow basis, the stock trades at 3.9X compared to the peer group's average of 15.9X, positioning the company favorably for value investors [7]. Zacks Rank and Style Scores - The company holds a Zacks Rank of 1 (Strong Buy), supported by rising earnings estimates [8]. - Collegium has a Value Score of A, a Growth Score of D, and a Momentum Score of C, resulting in a combined VGM Score of B [6][9]. Industry Comparison - The Medical - Drugs industry is performing well, ranking in the top 28% of all industries, providing a favorable environment for both Collegium Pharmaceutical and its peer, Catalyst Pharmaceuticals, Inc. (CPRX) [12]. - Catalyst Pharmaceuticals has a Zacks Rank of 2 (Buy) and has also shown strong earnings performance, beating consensus estimates by 33.33% [10][11].

Summary of Collegium Pharmaceutical FY Conference Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS:COLL) - **Key Products**: Jornay PM, Belbuca, Nucynta, Xtampza - **Industry**: Pharmaceutical, specifically focusing on ADHD and pain management medications Key Points Jornay PM Performance - **Growth Driver**: Jornay PM is identified as the primary growth driver for Collegium, with a unique profile as the only ADHD medication taken at night [4][5] - **Prescription Growth**: In Q3, prescriptions for Jornay PM grew by 20% year-over-year, with new writers increasing by 22% [4] - **Sales Guidance**: Full-year net sales guidance for Jornay PM was raised to $145 million-$150 million, reflecting a 46% growth year-over-year [5] - **Market Context**: The overall ADHD market consists of approximately 100 million prescriptions, growing at 6%-8% annually [12] Commercial Infrastructure - **Sales Force Expansion**: The sales team was expanded from 125 to 180 representatives to effectively target over 21,000 physicians, focusing on both psychiatrists and pediatricians [14][20] - **Target Demographics**: Currently, 80% of Jornay PM prescriptions are for pediatric and adolescent patients, with plans to shift towards a 70/30 split with adults over time [29][33] Market Access and Competition - **Payer Access**: Access to Jornay PM is favorable, with a split of two-thirds commercial and one-third Medicaid. Patients typically need to try generics before accessing the branded product [42] - **Gross-to-Net Ratio**: The gross-to-net ratio for Jornay PM is expected to be in the mid-60s, improved from previous expectations [49][53] Legacy Pain Business - **Belbuca Exclusivity**: The first potential generic competitor for Belbuca is expected in January 2027, with no current generic entrants meeting all necessary criteria [68][66] - **Nucynta and Xtampza**: Nucynta has a stable revenue base, while Xtampza has a significant barrier to entry for generics, with a current gross-to-net ratio in the mid-50% range [125][128] Strategic Priorities - **Capital Deployment**: Collegium focuses on three strategic priorities: accelerating Jornay growth, maximizing the pain franchise, and disciplined capital deployment [129][131] - **Business Development**: The company is actively seeking additional business development opportunities, particularly in ADHD and rare diseases, with a focus on assets that can generate over $300 million in peak sales [140][142] Future Outlook - **Investment Strategy**: Collegium aims to invest in commercial or near-commercial assets that align with its existing sales force, while also considering the addition of a specialty sales force for rare disease products [148][154] - **Development Stage Assets**: Currently, Collegium does not plan to take on development stage assets until achieving greater commercial scale [155] Additional Insights - **Market Dynamics**: The ADHD market is characterized by a high volume of prescriptions and a competitive landscape, with Collegium's differentiated product positioning providing a unique advantage [3][12] - **Patient Demographics**: The company is seeing a mix of switchers from other medications and some treatment-naive patients, indicating a growing acceptance of Jornay PM among prescribers [60]

Core Insights - Collegium Pharmaceutical, Inc. (COLL) has demonstrated strategic discipline and optimism, focusing on its pain-management franchise and ADHD product, Jornay PM, supported by significant capital investments [1] Share Buybacks Highlight Long-Term Confidence - The company has implemented an aggressive share buyback strategy, including a $25 million accelerated share repurchase deal in May and a new $150 million repurchase program authorized in July, reflecting a commitment to growth and returning capital to shareholders [2] Strengthening Governance and Commercial Expansion - Collegium is enhancing its corporate governance by refreshing its board, appointing Gino Santini as chairman and adding Nancy S. Lurker as a director, while also expanding its ADHD commercial operations with the deployment of approximately 180 trained sales representatives for Jornay PM [3] Disciplined Capital Allocation - The company is focusing on disciplined capital allocation, which includes paying down debt, engaging in opportunistic share repurchases, and prioritizing business development in areas with potential for long-term returns [4] Broadening Beyond Pain Management Amid Competition - Collegium is expanding beyond its traditional pain management focus, gaining traction in neuropsychiatry with Jornay PM, while facing competition from companies like Amneal Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. [5] Consistent Outperformance Reinforces Momentum - In Q3 2025, Collegium reported adjusted earnings of $2.25 per share, exceeding the Zacks Consensus Estimate of $1.88, and revenues of $209.36 million, surpassing the consensus estimate of $189.73 million, marking a consistent trend of beating revenue estimates over the past four quarters [6] Bottom Line - The year 2025 has been characterized by consolidation and strategic evolution for Collegium, positioning the company for sustainable, shareholder-focused growth rather than short-term gains [7] Summary of Recent Developments - Collegium has made significant advancements through share buybacks, governance changes, and expanded ADHD commercial efforts, deploying around 180 representatives for Jornay PM while maintaining disciplined capital allocation [8]

Summary of Collegium Pharmaceutical Conference Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS:COLL) - **Focus**: Chronic pain management and ADHD with five marketed products - **Revenue**: Expected to reach $780 million in 2025, representing a 24% year-over-year growth [1][3][11] Core Business Insights - **Flagship Products**: - Xtampza: Extended-release oxycodone with abuse-deterrent technology - Belbuca: Long-acting opioid using buprenorphine buccal film technology - Nucynta: Treats severe and persistent pain, including diabetic neuropathy - Jornay PM: Unique evening-dosed ADHD medication [2][3][11] - **Recent Acquisition**: IronSure in 2024, adding Jornay PM to the portfolio [2] Financial Performance - **Q3 2025 Results**: - Revenues: $209.4 million, up 31% year-over-year - Adjusted EBITDA: $133 million, up 27% year-over-year - Cash from operations: Nearly $80 million, total cash balance of $286 million [6][11] - **Debt Management**: - Net debt to adjusted EBITDA ratio down to 1.2 times, expected to be below 1 by year-end [7][12] Growth Strategy - **Three Core Pillars**: 1. Grow Jornay through strategic investments in sales and marketing 2. Maximize the value of the pain portfolio 3. Strategically deploy capital for business development, debt repayment, and share repurchases [4][12] - **Market Position**: - Jornay PM is the fastest-growing stimulant for ADHD, with a 20% growth in prescriptions [8][9] - Pain portfolio revenue growth: 10% for Belbuca and 2% for Xtampza in Q3 [11] Market Dynamics - **ADHD Market**: - Approximately 100 million prescriptions annually, with 90% being stimulant medications - Jornay PM has a unique evening dosing, leading to high differentiation and prescriber intent [7][8] - **Pain Management Market**: - Collegium's pain portfolio represents about half of the branded extended-release market - Minimal regulatory or clinical risks compared to peers [11][12] Shareholder Value - **Share Repurchases**: Over $220 million repurchased since 2021, with an authorization for an additional $150 million through 2026 [1][12] - **Future Outlook**: Confident in the strength and durability of the business, with robust revenue growth and strong cash flow generation expected [11][13]

Core Insights - Collegium Pharmaceutical, Inc. (COLL) is highlighted as a promising biopharma company, with a focus on its recent performance and potential investment opportunities [1]. Group 1: Company Overview - Collegium Pharmaceutical is being revisited for analysis after a previous article in March, indicating ongoing interest and developments in the company [1]. - The company is part of a model portfolio that includes 12-20 high upside biotech stocks, suggesting a strategic selection aimed at maximizing investor returns [1]. Group 2: Analyst Background - The analysis is led by an experienced market analyst with over 13 years in the biotech sector, specializing in high beta sectors that offer potentially large returns [1]. - The analyst is associated with The Biotech Forum, which provides live discussions on trade ideas and weekly updates on market commentary and portfolio performance [1].

Core Insights - Collegium Pharmaceutical reported Q3 CY2025 revenue of $209.4 million, exceeding Wall Street expectations by 31.4% year-on-year and beating analyst estimates by 10.7% [1][5] - The company raised its full-year revenue guidance to $780 million, which is 3.8% above analysts' estimates [1][5] - Non-GAAP profit per share was $2.25, surpassing analysts' consensus by 21% [1][5] Revenue and Financial Performance - Revenue for Q3 was $209.4 million compared to analyst estimates of $189.1 million, reflecting a 31.4% year-on-year growth [5] - Adjusted EPS was $2.25, beating analyst estimates of $1.86 by 21% [5] - Adjusted EBITDA reached $133 million, with a margin of 63.5%, exceeding analyst estimates of $118.2 million [5] - The company increased its full-year EBITDA guidance to $465 million, above analyst estimates of $442.6 million [5] - Operating margin improved to 29.7%, up from 21.9% in the same quarter last year [5] - Market capitalization stands at $1.28 billion [5] Product Performance and Strategic Outlook - Strong demand for ADHD medication Jornay PM and resilience in the pain management portfolio were key drivers of growth [3][4] - Jornay PM prescriptions grew by 20% year-over-year, aided by expanded sales efforts and targeted marketing [3] - Management expects continued momentum from Jornay PM and a stable outlook for pain products, with plans for incremental investments in sales and marketing [3][4] - Improvements in payer coverage and contract terms are anticipated to support profitability [3]

Core Insights - Collegium Pharmaceutical's shares increased by 11.6% following the announcement of strong Q3 2025 financial results, surpassing analyst expectations and raising full-year guidance [1][2] Financial Performance - The company reported net revenue of $209.4 million, reflecting a year-on-year increase of 31.4%, which exceeded Wall Street forecasts [2] - Collegium raised its full-year net revenue forecast to a range of $775 million to $785 million and adjusted EBITDA projection to between $460 million and $470 million [2] Market Reaction - The stock's movement indicates low volatility, with only 9 instances of greater than 5% movement in the past year, suggesting significant market impact from the recent news [4] - The stock has risen 44.5% year-to-date, reaching a new 52-week high of $41.36 per share [6] - An investment of $1,000 in Collegium shares five years ago would now be valued at $2,105 [6]